Skip to main content

Table 1 System suitability

From: Stability-indicating method development and validation for the concurrent determination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide by UPLC in bulk and tablet dosage forms

Parameters TAF COBI FTC DRV limit criteria
RSD of peak area (Injection repeatability) 0.2 0.8 0.5 0.2 < 2.0 for n ≥ 6
% RSD of retention time 0.442 0.394 0.503 0.437 < 1.0 for n ≥ 6
Tailing factor 1.2 1.2 1.366 1.264 T < 2
Plate count 5831.5 3093.4 3977.7 6053.2 N > 2000
Resolution 3.2 2.8 4.7 R > 2
  1. TAF tenofovir alafenamide, COBI cobicistat, FTC emtricitabine, DRV darunavir, n no. of determinations, T tailing factor, no. of plates, R resolution